John L. Marshall, MD, discusses the situations where patients could benefit from fam-trastuzumab deruxtecan-nxki as second-line treatment for locally advanced or metastatic HER2-positive gastric cancer.
Using Antibody-Drug Conjugates in Later-Line HER2+ Gastric Cancer
John L. Marshall, MD, discusses of the adverse event profile of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.
Bassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.
John Marshall, MD, discusses the DESTINY-Gastric01 study of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.